A Multi Center Study of Sexual Toxicities After Radiotherapy

Recruiting now

Conditions studied: Malignant Neoplasms

In brief

The purpose of this research is to understand how radiotherapy and other cancer treatments impact sexual function in female cancer patients and to try to answer a question about why some patients who receive radiotherapy are more likely to have side effects than others. The results of this study may improve our understanding of why sexual side effects occur and in turn develop predictive models and biomarkers of sexual side effects and other side effects that may impact sexual function. The results of this study may also lead to improvements in the techniques used to deliver radiotherapy or the development of interventions that will prevent or reduce sexual side effects and improve quality of life for female patients with cancer.

Key facts

Study ID

NCT05394428

Run by

Icahn School of Medicine at Mount Sinai

People needed

300

Starts

2022-10-04

Expected to finish

2027-08-31

Last updated by the study team

2026-06-22

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Patients with female sexual organs ages 18 and older.
• Patients must meet at least one of the following two criteria:
• have been sexually active in the 36 months prior to initiating cancer treatment.
• have the intent to be sexually active in the 24 months following treatment..
• Patients must be able to provide consent and be willing to participate.
• Patients must have primary anal, rectal, cervical, uterine, vaginal, or vulvar cancer planned to receive pelvic radiotherapy.** Patients must have an Eastern Cooperative Oncology Group performance status <=2.

You may not qualify if…

• planned for or undergone extensive pelvic surgery (e.g. pelvic exenteration, non-TME techniques, or surgeries otherwise affecting pudendal neurovasculature);
• have clinically or radiologically detectable widespread metastasis;
• have limited life expectancy due to comorbid disease;
• have a personal history of cancer other than non-melanoma skin cancer in the last 5 years;
• have contraindications or strong relative contraindications to radiotherapy at baseline as determined by the treating radiation oncologist (pregnancy, lactation, genetic susceptibility to cancer from ionizing radiotherapy, connective tissue disorders, inflammatory/irritable bowel disease, history of prior pelvic radiotherapy).
• have persistent, infectious gastroenteritis, colitis or gastritis;
• have persistent or chronic diarrhea of unknown etiology; have recurrent or untreated GI infection (clostridium difficile or H. pylori);
• have current or recurrent vaginal infection;
• have current or recent antibiotic use (within 2 months).
• Patients may be enrolled regardless of previous local or systemic treatments received prior to enrollment in the STAR Study.
• Patients may be enrolled on the STAR Study concurrently with another study or clinical trial.

Where it is running

• Emory University — Atlanta, Georgia, United States (enrolling)
• Icahn School of Medicine at Mount Sinai — New York, New York, United States (enrolling)
• M.D. Anderson Cancer Center — Houston, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.